Libtayo News & Analysis

Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth

Regeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.